[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=abafeaeece3421836ee801d3ace65008495066d8cd7f23afe37fb44170686c1c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752252360,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 135981339,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=abafeaeece3421836ee801d3ace65008495066d8cd7f23afe37fb44170686c1c"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target",
    "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, 2025, marking a significant progress in the treatment of relapsed or refractory multiple myeloma in patients who have undergone four or more prior therapies. The approval adds […]",
    "url": "https://finnhub.io/api/news?id=5e9b7d55c30fc1d9c2f887343c6814eb35e1b4cbdae0ec85cbac5cf6997e62aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752204393,
      "headline": "Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target",
      "id": 135866992,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, 2025, marking a significant progress in the treatment of relapsed or refractory multiple myeloma in patients who have undergone four or more prior therapies. The approval adds […]",
      "url": "https://finnhub.io/api/news?id=5e9b7d55c30fc1d9c2f887343c6814eb35e1b4cbdae0ec85cbac5cf6997e62aa"
    }
  }
]